Given that the principal aim of this study was to use the pIL-12 GET combination with anti-PD1 for generating robust functional T-cells (CD8+ PD1−), we tested the capacity of the expanded cytotoxic T-cells to kill targeted cancer cells. Here, CD8A is linked to cancer.